
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.

Your AI-Trained Oncology Knowledge Connection!


The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.

Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.

This comprehensive guide for oncologists covers the diagnosis, staging, treatment, and management of gastric cancer.

Published: June 1st 2016 | Updated: